Airport COVID-19 Testing of Travelers: An Island Destination Perspective
Purpose of Review To highlight recent literature on airport COVID-19 testing studies among travelers at international borders and to identify factors that may contribute to bias. Recent Findings Literature search shows vastly different study designs and goals for airport COVID-19 screening programs, with positivity rates ranging from 0.1 to 100%. Goals included detecting the maximum cases with enforced isolation, determining an accurate positivity rate among travelers, investigating alternative diagnostics, and evaluating pre-travel programs. Participation rates are in the low (27–40%) to high ranges (72–100%). Summary The implementation strategy differs depending on the primary goal. If the goal is to ban new cases or perform active surveillance of new variants, then it is reasonable to consider mandatory airport testing, or voluntary testing with genome sequencing and isolation. If the goal is to determine an accurate positivity rate among travelers or effectiveness of pre-travel programs, then it is reasonable to consider an anonymous, voluntary testing program (without associated isolation) to minimize self-selection bias or distortion of travelers..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Current infectious disease reports - 25(2023), 8 vom: 03. Juli, Seite 141-150 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hou, Amy T. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Border |
|---|
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1007/s11908-023-00809-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2144493014 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2144493014 | ||
| 003 | DE-627 | ||
| 005 | 20240118095320.0 | ||
| 007 | tu | ||
| 008 | 240118s2023 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11908-023-00809-5 |2 doi | |
| 035 | |a (DE-627)OLC2144493014 | ||
| 035 | |a (DE-He213)s11908-023-00809-5-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Hou, Amy T. |e verfasserin |0 (orcid)0000-0003-3900-3842 |4 aut | |
| 245 | 1 | 0 | |a Airport COVID-19 Testing of Travelers: An Island Destination Perspective |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Purpose of Review To highlight recent literature on airport COVID-19 testing studies among travelers at international borders and to identify factors that may contribute to bias. Recent Findings Literature search shows vastly different study designs and goals for airport COVID-19 screening programs, with positivity rates ranging from 0.1 to 100%. Goals included detecting the maximum cases with enforced isolation, determining an accurate positivity rate among travelers, investigating alternative diagnostics, and evaluating pre-travel programs. Participation rates are in the low (27–40%) to high ranges (72–100%). Summary The implementation strategy differs depending on the primary goal. If the goal is to ban new cases or perform active surveillance of new variants, then it is reasonable to consider mandatory airport testing, or voluntary testing with genome sequencing and isolation. If the goal is to determine an accurate positivity rate among travelers or effectiveness of pre-travel programs, then it is reasonable to consider an anonymous, voluntary testing program (without associated isolation) to minimize self-selection bias or distortion of travelers. | ||
| 650 | 4 | |a SARS-CoV2 | |
| 650 | 4 | |a Screening | |
| 650 | 4 | |a International | |
| 650 | 4 | |a Border | |
| 650 | 4 | |a Surveillance | |
| 650 | 4 | |a Quarantine | |
| 650 | 4 | |a Isolation | |
| 700 | 1 | |a Pang, Genevieve C. |0 (orcid)0000-0002-8611-1283 |4 aut | |
| 700 | 1 | |a Mills, Kristin M. |4 aut | |
| 700 | 1 | |a Bayudan, Krizhna L. |4 aut | |
| 700 | 1 | |a Moore, Dayna M. |0 (orcid)0009-0007-2248-3559 |4 aut | |
| 700 | 1 | |a Medina, Luz P. |4 aut | |
| 700 | 1 | |a Pang, Lorrin W. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current infectious disease reports |d Springer US, 1999 |g 25(2023), 8 vom: 03. Juli, Seite 141-150 |w (DE-627)320599086 |w (DE-600)2019948-X |x 1523-3847 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:8 |g day:03 |g month:07 |g pages:141-150 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s11908-023-00809-5 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2023 |e 8 |b 03 |c 07 |h 141-150 | ||